Anti-BCL2 [bcl-2/100] mAb

Monoclonal antibody directed against both isoforms of BCL-2 protein.

Contributors

Inventor Institute
Jacqueline Cordell University of Oxford
Cat. #: 151406
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Apoptosis and autophagy;Cancer;Cell signaling and signal transduction;Metabolism
Application: IHC ; WB
Target: Bcl2
Reactivity: Human
Clone: bcl-2/100
Host: Mouse
Class: Monoclonal
Primary citation: Pezzella et al. 1990. The American journal of pathology, 137(2), 225–232. PMID: 2201196
Product description: Monoclonal antibody directed against both isoforms of BCL-2 protein.
Conjugation: Unconjugated
Isotype: IgG1
Immunogen: Synthetic peptide of amino acids 41-54 of human bcl-2 oncoprotein
Immunogen Uniprot ID: P10415
Myeloma used: P3/NS1/1-Ag4.1
Target background: The pro-survival protein BCL2 derives its name from B-cell lymphoma 2, as it is the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas. There are two isoforms, alpha and beta, of Bcl-2 have been identified and are a result of alternative splicing at the C-terminus. BCL-2 protein is involved in apoptosis, and inhibits the function of pro-apoptotic proteins such as Bax and Bak. Damage to the Bcl-2 gene has been identified as a cause of a number of cancers, including melanoma, breast, prostate, chronic lymphocytic leukaemia, and lung cancer, and a possible cause of schizophrenia and autoimmunity. It is also a cause of resistance to cancer treatments. This antibody recognises both the alpha and beta isoforms of BCL-2.
Format: Liquid
Concentration: 8 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
Shipping conditions: Dry ice
References:

Hirpara et al. 2020. Redox Biol. 30:101403. PMID: 31954371.

Steinbach et al. 2020. PLoS One. 15(1):e0227676. PMID: 31935257.

Jeffery et al. 2017. Clin Exp Immunol. 188(3):394-411. PMID: 28176332.

Soilu-Hänninen et al. 1999. J Neurosci. 19(12):4828-38. PMID: 10366617.

Navratil et al. 1995. J Clin Pathol. 48(1):18-21. PMID: 7706514.

Ashton-Key et al. 1995. Histopathology. 26(1):75-8. PMID: 7713486.

Piris et al. 1994. Br J Cancer. 69(2):337-41. PMID: 8297731.

Leek et al. 1994. Br J Cancer. 69(1):135-9. PMID: 8286195.

de Jong et al. 1994. Cancer Res. 54(1):256-60. PMID: 8261449.

Pezzella et al. 1993. N Engl J Med. 329(10):690-4. PMID: 8393963.

Doussis et al. 1993. Am J Clin Pathol. 99(6):663-7. PMID: 8322700.

Pezzella et al. 1993. Histopathology. 22(1):39-44. PMID: 8436340.

Gaulard et al. 1992. Am J Pathol. 140(5):1089-95. PMID: 1374590.

Pezzella et al. 1992. Br J Cancer. 65(1):87-9. PMID: 1733447.

Pezzella et al. 1990. Lancet. 336(8729):1510-1. PMID: 1979117.

Pezzella et al. 1990. The American journal of pathology, 137(2), 225–232. PMID: 2201196

Images

View Gallery

Related Tools for Antibodies

Cat. # Tool Name
151019 Anti-Mos [S3.1] Key Info View Tool
151025 Anti-Vascular endothelium [10] Key Info View Tool
151039 Anti-Integrin aVb3 [23C6] Key Info View Tool
151017 Anti-MBP [R29.6] Key Info View Tool
151038 Anti-Cytochrome P450 4A2, 4A3 [Clo4] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.